Market Overview

UPDATE: Piper Jaffray Downgrades Synageva to Neutral on Lack of Near-Term Catalysts

Related GEVA
UPDATE: Morgan Stanley Reiterates on Synageva BioPharma as Brain-Blood Barrier Study is Good Next Step
UPDATE: Synageva Biopharma™ Announces 2M Share Proposed Public Offering of Its Common Stock

Piper Jaffray reduced its rating on Synageva (NASDAQ: GEVA) from Overweight to Neutral and lowered its price target from $66 to $57.

Piper Jaffray noted, "We are downgrading GEVA shares to Neutral from Overweight and reducing our price target to $57 from $66 as we see absence of meaningful news flow from Synageva following commencement of Phase III CESD trial in January 2013. While we remain positive on GEVA shares over the longer term we believe shares will likely remain rangebound as the Phase III trial progresses. We look to get more constructive on GEVA shares as we approach Phase II/III data in Wolman's disease, expected in 2014."

Synageva closed at $47.87 on Wednesday.

Posted-In: Piper JaffrayAnalyst Color Downgrades Pre-Market Outlook Analyst Ratings

 

Most Popular

Related Articles (GEVA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free